Product logins

Find logins to all Clarivate products below.


Metastatic esophageal cancer remains a subpopulation for which few treatment options exist. For decades, treatment was limited to chemotherapy-based regimens such as FOLFOX and DCF, but the recent approvals of the immune checkpoint inhibitors Keytruda (Merck & Co.) and Opdivo (Bristol Myers Squibb) as single agents and in combination with chemotherapy are beginning to change the treatment landscape. Nevertheless, substantial need remains for more-efficacious treatments for metastatic esophageal cancer, particularly for tumors with low PD-L1 expression.

QUESTIONS ANSWERED

  • How satisfied are U.S. and European medical oncologists with current treatment options for metastatic esophageal cancer?
  • What are the treatment drivers and goals most likely to influence the choice of therapy for metastatic esophageal cancer?
  • How do current therapies, such as Keytruda and Opdivo, perform on key clinical attributes, and what are the hidden opportunities for drug developers in this patient population?
  • What trade-offs are U.S. and European medical oncologists willing to make across key clinical attributes and pricing when considering hypothetical target product profiles for metastatic esophageal cancer?

PRODUCT DESCRIPTION

Provides quantitative insight into U.S. and European physician perceptions of key treatment drivers and goals and the current level of unmet need for a specific disease. Commercial opportunities are analyzed, and the extent to which emerging therapies may capitalize on these opportunities is evaluated.

Markets covered: United States, United Kingdom, France, Germany.

Primary research: Survey of 62 U.S. and 30 European medical oncologists fielded in April 2022.

Key companies: Bristol Myers Squibb, Merck & Co.

Key drugs: Opdivo, Keytruda, and trastuzumab.

Related Market Assessment Reports

Report
Psoriasis – Geographic Focus: China – Psoriasis | China In-Depth | China | 2025
Psoriasis is a chronic dermatologic condition with rising prevalence in China, particularly in urban areas where heightened awareness and improved access to care have led to higher diagnosis rates…
Report
Chronic Kidney Disease – Geographic Focus: China – Chronic Kidney Disease – China In-Depth (China)
Chronic kidney disease (CKD) is an irreversible condition requiring lifelong management. In China, CKD is notably widespread, particularly among older adults and those with chronic risk factors…
Report
Type 2 Diabetes – Geographic Focus: China – Type 2 Diabetes – China In-Depth (China)
In China, type 2 diabetes (T2D) continues to be a leading public health concern, with the highest global prevalence. Biguanides continue to dominate the market, but the use of SGLT-2 inhibitors and…
Report
Eosinophilic Esophagitis – Current Treatment – Treatment Algorithms: Claims Data Analysis – Eosinophilic Esophagitis (US)
Eosinophilic esophagitis (EoE) is a chronic allergic inflammatory condition of the esophagus, marked by an accumulation of eosinophils. This can lead to difficulty swallowing and potentially…
Report
Metabolic Dysfunction-Associated Steatohepatitis – Unmet Need – Unmet Need – Metabolic Dysfunction-Associated Steatohepatitis (US/EU)
Metabolic dysfunction-associated steatohepatitis (MASH), previously known as nonalcoholic steatohepatitis (NASH), has the potential to be a large and lucrative therapy market owing to the disease…